The US Food and Drug Administration on Thursday announced two revised doses per vial for the Moderna COVID-19 Vaccine to positively impact the supply of the vaccine to provide more vaccine doses to communities.
According to the agency, the first revision clarifies the number of doses per vial for the vials that are currently available, in that the maximum number of extractable doses is 11, with a range of 10-11 doses. The second revision authorizes the availability of an additional multi-dose vial in which each vial contains a maximum of 15 doses, with a range of 13-15 doses that can potentially be extracted.
Based on the type of syringes and needles used to extract each dose, there may not be sufficient volume to extract more than 10 doses from the vial containing a maximum of 11 doses or more than 13 doses from the vial containing a maximum of 15 doses. However, the dosing regimen remains unchanged. The vaccine is administered as a two-dose series, 0.5 ml each dose, one month apart, added the agency.
In conjunction, the Fact Sheet for Healthcare Providers Administering Vaccine and Prescribing Information have been revised to reflect the new information to help frontline workers administering COVID-19 vaccines understand the number of doses that can be extracted per vial, concluded the agency.
Merck to acquire Terns Pharmaceuticals for USD6.7bn
Philips launches integrated IntraSight Plus platform to enhance coronary intervention efficiency
Hope Medicine reports first patient dosed in Phase III trial of HMI-115
Orsini chosen as single-source specialty pharmacy partner for Glaukos' Epioxa
Futura Medical reports positive home user test results for Eroxon and Intense variant
GSK secures Japan Orphan Drug status for lung cancer ADC
Belief BioMed enters exclusive partnership with Grand Life Sciences for haemophilia A treatment
Glaukos launches Epioxa to advance incision-free treatment for keratoconus
Sanofi's venglustat receives FDA Breakthrough Therapy designation for type 3 Gaucher disease
Sentynl Therapeutics and PRG S&T enter licensing agreement for potential HGPS treatment
CMIC agrees agentic AI partnership with Bluenote
Biofrontera reports Phase 2b data for Ameluz photodynamic therapy in acne vulgaris treatment
Precision BioSciences receives FDA Fast Track designation for PBGENE-DMD